October 8, 2016 / 8:41 AM / 9 months ago

BRIEF-Novo Nordisk says U.S. FDA requests more information on faster-acting insulin aspart

1 Min Read

Oct 8 (Reuters) - Novo Nordisk A/S

* Says Novo Nordisk received complete response letter from U.S. Food and Drug Administration (FDA) regarding New Drug Application for faster-acting insulin aspart.

* Says FDA requests additional information related to analysis of immunogenicity and clinical pharmacology data before review of New Drug Application can be completed.

* Says drug application for aspart was submitted to the FDA in December 2015.

* Says insulin aspart is currently also under review in the EU, Switzerland, Canada, Brazil, South Africa and Argentina. Source text for Eikon: Further company coverage: (Reporting by Jacob Gronholt-Pedersen; editing by Mark Heinrich)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below